Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 3/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258808 | 0.84 | KDM4E (0.54) | CXCR1CXCR2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6638177 | 0.81 | CXCR1 (0.55) | CXCR1CXCR2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2549786 | 0.80 | KDM4E (0.57) | CXCR1CXCR2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12476341 | 0.79 | CXCR1 (0.61) | CXCR1CXCR2SMN1; SMN2POLBNNMT | |
| SCHEMBL2558998 | 0.78 | CXCR1 (0.51) | CXCR1CXCR2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL31119746 | 0.77 | TSHR (0.43) | CXCR1CXCR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22952872 | 0.77 | SMN1; SMN2 (0.43) | CXCR1CXCR2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9400043 | 0.76 | CXCR1 (0.50) | CXCR1CXCR2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2584585 | 0.76 | CXCR1 (0.50) | CXCR1CXCR2SMN1; SMN2 | |
| SCHEMBL6638331 | 0.76 | CXCR1 (0.50) | CXCR1CXCR2SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3956322-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-112047957-B | Substituted pyrimidinediones and their use | 广东东阳光药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-112047957-A | Substituted pyrimidinediones and their use | 广东东阳光药业有限公司 | 2020-12-08 | — | — | CN | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| EP-1122244-B1 | Uracil compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-6537948-B1 | Have a wide range of herbicidal spectrum, and causes no phytotoxicity on crops | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| EP-1122244-A1 | Uracil compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | CXCR1 491/4885CXCR2 678/4885SMN1; SMN2 4166/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | CXCR1 131/4885CXCR2 368/4885SMN1; SMN2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.